Bonfitto Pedro Henrique Leite, Rodrigues Beatriz Alves Guerra, Siqueira Natalia Souza Nunes, Genaro Livia Moreira, Rodrigues Bruno Lima, Oliveira Priscilla de Sene Portel, Martinez Carlos Augusto Real, Ayrizono Maria de Lourdes Setsuko, Leal Raquel Franco
Inflammatory Bowel Disease Research Laboratory, Gastrocenter, Colorectal Surgery Unit, School of Medical Sciences, University of Campinas (Unicamp) Campinas 13083-878, São Paulo, Brazil.
Am J Cancer Res. 2024 Nov 15;14(11):5133-5153. doi: 10.62347/PJNU8987. eCollection 2024.
Colorectal cancer (CRC) is one of the most widespread tumor types, and it stands as the second leading cause of disease-related mortality globally. Due to its adverse effects, which lead to low patient adherence, new alternatives to conventional chemotherapy and radiotherapy treatments are being studied. Since, in most cases, platelets are positively involved in the persistence and progression of CRC, several elements of the platelet signaling pathway have been considered possible therapeutic targets. The present study assembles the main treatments for CRC and investigates the cellular mechanisms involved in the interaction between blood platelets and cancer cells. Additionally, this review cites other articles that propose possible therapeutic targets in the platelet activation pathways to be explored. Despite the reported benefits of antithrombotic therapy on CRC progression, some studies have warned about an increased bleeding risk and CRC incidence and highlight the importance of controlling this therapy through diagnostic tests. However, their high cost is still a significant obstacle to the population's access from low Human Development Index (HDI) countries. Many research groups have studied platelet signaling pathways in depth to develop a safer, more effective, and affordable therapy for the population.
结直肠癌(CRC)是最常见的肿瘤类型之一,也是全球疾病相关死亡的第二大主要原因。由于其不良影响导致患者依从性低,目前正在研究传统化疗和放疗的新替代方案。因为在大多数情况下,血小板在CRC的持续发展和进展中起积极作用,所以血小板信号通路的几个元件已被视为可能的治疗靶点。本研究汇总了CRC的主要治疗方法,并研究了血小板与癌细胞相互作用所涉及的细胞机制。此外,本综述引用了其他文章,这些文章提出了血小板激活途径中有待探索的可能治疗靶点。尽管抗血栓治疗对CRC进展有报道的益处,但一些研究警告了出血风险增加和CRC发病率上升,并强调了通过诊断测试控制这种治疗的重要性。然而,其高昂的成本仍然是人类发展指数(HDI)较低国家的人群获得治疗的重大障碍。许多研究小组深入研究了血小板信号通路,以开发一种更安全、更有效且负担得起的治疗方法。